Hangzhou Alltest Biotech Co., Ltd. Class A

As of June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A carries a market capitalization of 3.26B, placing it among publicly traded companies globally. Its enterprise value stands at 1.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hangzhou Alltest Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A has 79.28M shares outstanding.

As of June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 21.16. The price-to-sales ratio is 3.63, and the price-to-book ratio stands at 0.87.

As of June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A trades at an EV/EBITDA multiple of 6.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.14B versus a market cap of 3.26B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A maintains a current ratio of 11.20, meaning it holds 11.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.19, indicating conservative leverage, while an interest coverage ratio of 742.71 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A posted a return on equity (ROE) of 3.94, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.86 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.71, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.95, useful for judging operating efficiency across full business cycles. The company generates approximately 898,136.39 in revenue per employee across its workforce of 986.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.51 indicates how many times Hangzhou Alltest Biotech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A recorded 22.63M in income tax expense. That works out to an effective tax rate of 12.96, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 174.54M, leaving 152.02M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A's stock has declined approximately 32.94% over the past 52 weeks. The 50-day moving average sits at 47.10, while the 200-day moving average is 54.42.

Over the twelve months ended June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A generated 885.79M in revenue and converted that into 152.02M in net income, yielding earnings per share of 1.94. EBITDA reached 175.00M, while operating income came in at 149.85M.

As of June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A holds 2.12B in cash and equivalents against 7.03M in total debt, resulting in a net debt position of -1.85B. Total book value stands at 3.76B, with working capital of 2.34B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A posted a gross margin of 49.73, reflecting its pricing power and cost economics. The operating margin of 16.92 and net profit margin of 17.16 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A paid dividends of 1.00 per share. The dividend payout ratio of 51.59 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Hangzhou Alltest Biotech Co., Ltd. Class A's most recent stock split took place on June 9, 2023 with a 25:37 split ratio.

As of June 30, 2026, Hangzhou Alltest Biotech Co., Ltd. Class A has an Altman Z-Score of 10.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.